IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a top biotech stock with high potential, as per J.P. Morgan analyst Anupam Rama who maintained a Buy rating and $74 price target. The company partnered with ATTMOS for an AI-driven drug discovery platform. UBS analyst David Dai reiterated a Buy rating and set a price target of $50. IDEAYA focuses on oncology precision medicine, with IDE196 as a key product candidate. While IDYA shows promise, some AI stocks may offer greater upside potential. For more insights on potential stock investments, explore articles on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Read more at Yahoo Finance: J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA)